Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating on October 28. Joseph Stringer has ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

A new hydrophobic tag enables the high-purity production of a key intermediate in the chemical synthesis of capped mRNA and ...

Production tips from Crystal Bio, TriLink Biotechnologies, Ginkgo Bioworks, Quantoom Biosciences, and Parexel.

Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older – ...

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...